Spyre Therapeutics (SYRE) Stock Price, Quote, News & History | Benzinga

SPY764.73+0.10%QQQ743.60+0.21%BTC/USD85,879.58+1.21%DIA508.66+0.01%GLD383.30+0.14%TLT77.70−0.01%

Spyre Therapeutics Inc (SYRE) Stock Price, Quote, News & History

SYRENASDAQ

Trade with Public

Trade with Public

$89.93

0.901.01%

Last update: Oct 1, 4:20 PM

$89.93

0.901.01%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$89.13

Close

$89.93

Volume / Avg.

1.66M / 1.15M

Day Range

$87.25 - $94.06

52 Wk Range

15.86 - 110.18

Market Cap

$7.76B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

50

Short Interest

15.06%

Days to Cover

11.58

Recent Spyre Therapeutics Inc News

Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday

U.S. stocks rose as Nasdaq gained 100+ points; HPE jumped 5.1% on stronger networking guidance and a Vultr AI rack order.

Avi Kapoor

Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock Tumbles

Spyre Therapeutics shared Phase 2 SKYWAY trial data for SPY072 in rheumatoid arthritis. The therapy missed internal priority benchmarks.

Vandana Singh

Intuit, Zoom, Qfin Holdings And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

US stock futures mixed, Intuit shares dip 11.7% after reporting Q4 revenue of $4.35B and adjusted earnings of $4.03/share. FY27 guidance below estimates. Other stocks moving lower in pre-market trading.

Avi Kapoor

Why JOYY Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

JOYY Inc (NASDAQ: JOYY) reported Q2 earnings below estimates, but beat revenue expectations. Shares rise 3.6% in pre-market trading.

Avi Kapoor

Target To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday

Wall Street analysts changed outlook on top names. See complete view of all changes, upgrades, downgrades on analyst ratings page.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-208.94M

Investing Cash Flow (TTM)

-463.74M

Financing Cash Flow (TTM)

753.03M

Free Cash Flow (TTM)

-208.94M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

80.35M

Analyst Trends and Forecast

3

Jun

1

Jul

7

Aug

2

Sep

2

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$6.93B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

8.31

Earnings Yield % (TTM)

-2.13%

Earnings Yield % (FWD)

-4.73%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$10.83

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$162.01M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-